$ --

Fruquintinib is a targeted therapy independently developed in China, specifically for third-line treatment of advanced colorectal and gastric cancer. It blocks cancer cell growth by inhibiting tumor angiogenesis. It demonstrated outstanding performance in the FRESCO and FRESCO-2 studies, significantly prolonging patient survival with a good safety profile. Approved by the FDA in November 2023 and by the EU in June 2024, it became the first original Chinese anticancer drug to simultaneously gain recognition in the three major markets of China, the US, and Europe. Furthermore, it has shown potential in the treatment of gastric cancer, with its combination regimen with paclitaxel receiving recognition from top international journals. This drug not only brings new hope to patients, but also marks a leap forward in China's drug research and development from catching up to keeping pace.